LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

Search

Allogene Therapeutics Inc

Open

SectorHealthcare

1.1 -2.65

Overview

Share price change

24h

Current

Min

1.12

Max

1.14

Key metrics

By Trading Economics

Income

8.8M

-51M

Profit margin

272,450

Employees

226

EBITDA

-335K

-57M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+724.56% upside

Dividends

By Dow Jones

Next Earnings

6 Nov 2025

Market Stats

By TradingEconomics

Market Cap

25M

251M

Previous open

3.75

Previous close

1.1

News Sentiment

By Acuity

41%

59%

152 / 371 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Allogene Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

8 Sept 2025, 23:59 UTC

Acquisitions, Mergers, Takeovers

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8 Sept 2025, 22:02 UTC

Major Market Movers

Microsoft Signs $17.4 Billion AI Deal With Nebius

8 Sept 2025, 17:01 UTC

Major Market Movers

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8 Sept 2025, 17:01 UTC

Major Market Movers

Tron Shares Rise After New Investment From Bravemorning

8 Sept 2025, 16:14 UTC

Major Market Movers

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8 Sept 2025, 16:13 UTC

Major Market Movers

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8 Sept 2025, 23:12 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 Sept 2025, 23:12 UTC

Market Talk

Global Equities Roundup: Market Talk

8 Sept 2025, 23:12 UTC

Market Talk

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8 Sept 2025, 22:56 UTC

Market Talk

Worst May Be Over for New Zealand Retailers -- Market Talk

8 Sept 2025, 22:23 UTC

Market Talk

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8 Sept 2025, 21:51 UTC

Market Talk

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8 Sept 2025, 21:47 UTC

Major Market Movers

Microsoft Signs $17.4B AI Deal With Nebius

8 Sept 2025, 21:33 UTC

Acquisitions, Mergers, Takeovers

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8 Sept 2025, 21:20 UTC

Acquisitions, Mergers, Takeovers

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8 Sept 2025, 21:19 UTC

Acquisitions, Mergers, Takeovers

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8 Sept 2025, 21:18 UTC

Acquisitions, Mergers, Takeovers

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8 Sept 2025, 20:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

8 Sept 2025, 19:33 UTC

Market Talk

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8 Sept 2025, 19:22 UTC

Market Talk

U.S. Natural Gas Futures Settle Higher -- Market Talk

8 Sept 2025, 19:02 UTC

Market Talk

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8 Sept 2025, 18:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 Sept 2025, 18:24 UTC

Market Talk

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8 Sept 2025, 17:29 UTC

Market Talk

Mexican Inflation Seen Little Changed in August -- Market Talk

8 Sept 2025, 16:59 UTC

Market Talk
Acquisitions, Mergers, Takeovers

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8 Sept 2025, 16:36 UTC

Market Talk

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8 Sept 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

8 Sept 2025, 16:16 UTC

Earnings

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8 Sept 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 Sept 2025, 16:04 UTC

Market Talk

Global Equities Roundup: Market Talk

Peer Comparison

Price change

Allogene Therapeutics Inc Forecast

Price Target

By TipRanks

724.56% upside

12 Months Forecast

Average 9.4 USD  724.56%

High 14 USD

Low 7 USD

Based on 10 Wall Street analysts offering 12 month price targets forAllogene Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

10 ratings

7

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

1.18 / 1.69Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

152 / 371 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
help-icon Live chat